site stats

Cingulate therapeutics filing

WebApr 11, 2024 · On April 04, 2024, Cingulate Inc. (NASDAQ: CING) announced it had completed the first cohort of its Phase 3 adult onset and duration trial of its lead candidate, CTx-1301 (dexmethylphenidate), for attention deficit/hyperactivity disorder (ADHD). The Phase 3 CTx-1301-022 study (NCT05631626) assesses the onset and duration of CTx … WebMar 10, 2024 · Inside Cingulate Inc.'s 10-K Annual Report: Financial - Expense Highlight. We have experienced, and will continue to experience, increased expenses associated …

Home - Cingulate Inc

WebCINGULATE THERAPEUTICS LLC: TEXAS FOREIGN LIMITED-LIABILITY COMPANY (LLC) WRITE REVIEW: Address: 1901 W. 47th Place, Ste 310 Kansas City, KS 66205: Registered Agent: C T Corporation System: Filing Date: June 06, 2024: File Number: 0803337838: Contact Us About The Company Profile For Cingulate Therapeutics LLC division 2 big game hunter https://stankoga.com

Cingulate Therapeutics LLC - DE, KS, and TX - Bizapedia

WebJul 10, 2024 · About Cingulate Therapeutics. ... Cingulate anticipates filing INDs for both products in the first quarter of 2024 and will pursue approval via the accelerated 505 (b)(2) regulatory pathway. ... WebMar 31, 2024 · The transplantation of neural progenitors into a host brain represents a useful tool to evaluate the involvement of cell-autonomous processes and host local cues in the regulation of neuronal differentiation during the development of the mammalian brain. Human brain development starts at the embryonic stages, in utero, with unique … WebDec 8, 2024 · Cingulate Inc. is a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to … division 2 biozone insulated jacket

SEC FORM D/A

Category:Cingulate Therapeutics Appoints Laurie Myers, PhD, MBA as …

Tags:Cingulate therapeutics filing

Cingulate therapeutics filing

Cingulate Inc. Announces Pricing of $25.0 Million Initial Public …

WebThe Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. ... Cingulate … WebCingulate currently has two (2) product candidates, CTX-1301 and CTX-1302, that are being developed to serve the approximate $18 billion annual U.S. ADHD market. A third product candidate, CTX-2103, is being developed to serve the roughly $5 billion U.S. … 10 Mar 2024 Cingulate Inc. Reports Fourth Quarter and Full Year 2024 Financial … Pipeline Overview. Cingulate® completed a proof-of-concept trial in human subjects … Cingulate Inc. 1901 W 47th Place Kansas City, KS 66205 (913) 942-2300 … Shane J. Schaffer, PharmD is a Co-Founder of Cingulate Therapeutics and … About Cingulate®. Cingulate® (CTx®)is a Phase 3 clinical stage … Mr. Gallagher is a Co-Founder of Cingulate Therapeutics and serves as a member … The Investor Relations website contains information about Cingulate Inc's …

Cingulate therapeutics filing

Did you know?

WebUncategorized (1) Contracts. Master Services Agreement between Cingulate Therapeutics LLC and Societal CDMO, Inc., dated October 24, 2024 (Filed With SEC on October 25, 2024) Promissory Note, dated August 9, 2024, between Cingulate Therapeutics, LLC and Werth Family Investment Associates LLC (Filed With SEC on August 11, 2024) … WebJun 29, 2024 · The most recently filed 13Fs

WebSep 24, 2014 · Somerset, N.J. – September 24, 2014 — Catalent Pharma Solutions has reached an exclusive development and licensing agreement with privately held biopharmaceutical company, Cingulate Therapeutics (CTx), to support the development of a series of new prescription pharmaceutical products for the treatment of Attention … WebApr 6, 2024 · Cingulate's stock was trading at $1.00 at the beginning of the year. Since then, CING stock has decreased by 3.8% and is now trading at $0.9619. View the best growth stocks for 2024 here.

WebThe Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. ... Cingulate Therapeutics: Street Address 1 Street Address 2; 1901 W. 47th Place: Third Floor: City State/Province/Country ZIP/PostalCode Phone Number of Issuer; Kansas City: … WebFind the latest Cingulate Inc. (CING) stock quote, history, news and other vital information to help you with your stock trading and investing.

WebAbout Cingulate®. Cingulate® (CTx®)is a Phase 3 clinical stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform to build and advance a pipeline of branded next-generation pharmaceutical products.These will be designed to improve the lives of patients suffering from frequently diagnosed …

WebAmendment to Employment Agreement, effective April 1, 2024, between Cingulate Therapeutics LLC and Raul R. Silva; Cingulate Inc. Reports First Quarter 2024 Results and Provides Clinical and Business Update Announcement of First Subject Dosing for Anxiety Candidate CTx-2103 to Extend the Application of the Precision Timed Release™ … craftsman 3 stage snowblower reviewWebApr 2, 2024 · About Cingulate Therapeutics. ... Cingulate anticipates filing INDs for both assets in the third and fourth quarters of 2024 and will pursue approval via the accelerated 505(b)(2) regulatory ... division 2 black tusk bountiesWebThe Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. ... Cingulate Therapeutics: Street Address 1 Street Address 2; 1901 W. 47th Place: SUITE 300: City State/Province/Country ZIP/PostalCode Phone Number of Issuer; KANSAS CITY: … craftsman 3 ton aluminum floor jack partsWebSep 9, 2024 · Cingulate Inc. S-1 Filing information. Filed on 9 September 2024 SEC Edgar 000149315221022284 Exhibits & attachments & exports. ... Top menu > File > Make a … division 2 blauer bildschirm buildWebOct 13, 2024 · Cingulate Therapeutics' IPO date and price. Cingulate is expected to start trading on Oct. 15. The company now plans to raise $40 million by offering 4.4 million … division 2 black fridayWebThe Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. ... Cingulate Therapeutics: Street Address 1 Street Address 2; 6 SOUTH STREET: SUITE 203: City State/Province/Country ZIP/PostalCode Phone Number of Issuer; MORRISTOWN: NEW … craftsman 3 ton car jackWebMar 30, 2024 · (a) the Company’s latest annual report on Form 10-K filed pursuant to Section 13(a) or 15(d) of the Exchange Act for the fiscal year ended December 31, 2024, as filed with the Commission on ... craftsman 3 ton floor jack lowes